A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Clinical trial NCT04576117 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04576117
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma

Start date: 2021-02-16
Primary completion: 2026-12-30
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.